Canaccord Genuity Group Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $164.00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price upped by Canaccord Genuity Group from $154.00 to $164.00 in a research note issued to investors on Thursday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. NBIX has been the subject of a number of other reports. Barclays upped their […]

Related Keywords

United States ,Neurocrine Biosciences ,Redhawk Wealth Advisors Inc ,Barclays ,Cantor Fitzgerald ,Goldman Sachs Group ,Needham Company ,Canaccord Genuity Group ,Neurocrine Biosciences Inc ,Roman Butler Fullerton Co ,Securities Exchange Commission ,Free Report ,Genuity Group ,Moderate Buy ,Get Free Report ,Director Richard ,Exchange Commission ,Wealth Advisors ,Minvest Partners ,Roman Butler Fullerton ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Canaccord Genuity Group Inc ,